Discover the importance of vision, genetic eye disorders, and RNA-based therapies for precision treatment in India and ...

The FDA has granted RMAT designation to Beacon Therapeutics’ gene therapy, laru-zova, for treating X-linked retinitis pigmentosa (XLRP).

Beacon Therapeutics Holdings Limited ('Beacon Therapeutics' or 'the Company'), a leading ophthalmic gene therapy company with ...

The NPI-001 (N-acetylcysteine amide) tablets are a proprietary investigational therapy for the treatment of patients with ...

Night blindness, or nyctalopia, is the inability to see well in low light conditions, often signalling an underlying issue ...

A multidisciplinary team of researchers from the Istituto Italiano di Tecnologia (IIT-Italian Institute of Technology) and ...

A synthetic molecule created in Italy has proven capable to reawakening retinal neurons to stave off degenerative illnesses ...

A drug that receives Fast Track designation may benefit from more frequent interactions with the FDA throughout drug development. In addition, the Fast Track program allows for Accelerated Approval ...

A multidisciplinary team of researchers from the Istituto Italiano di Tecnologia (IIT-Italian Institute of Technology) and ...

Inherited eye disorders such as retinitis pigmentosa (RP) leave millions grappling with progressive vision loss. At the heart ...

Two new compounds may be able to treat retinitis pigmentosa, a group of inherited eye diseases that cause blindness. The ...